Skip to content

Released Nov 7, 2012, after the close

10-Q filed Nov 7, 2012, 38 days after period end · 0001144204-12-060041

Q3 2012 · 10-Q
Revenue$3.72M+229.0% vs Q3 2011−85.7% vs Q2 2012
Net Income-$5.48MN/M vs Q3 2011N/M vs Q2 2012
EPS Diluted$0.06N/M vs Q3 2011−40.0% vs Q2 2012
Gross Profit$3,023,000+346.5%
Operating Income-$5,560,000N/M
Operating Cash Flowderived-$8,029,000N/M
Free Cash Flowderived-$8,799,000N/M
Margins · derived
Gross margin81.2%+21.4 pt vs Q3 2011
Operating margin-149.3%+625.2 pt vs Q3 2011
Net margin-147.1%+636.9 pt vs Q3 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2012Q3 2011Q3 2010
Revenue$3.72M$1.13M$3.18M
Net Income-$5.48M-$8.88M-$2.47M
EPS Diluted$0.06-$0.10$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR